| Date | Title | | | 05/07/13 | Luminex Corporation To Present At Upcoming Investment Conferences| AUSTIN, Texas, May 7, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at three upcoming investment conferences:
The UBS Global Healthcare Conference on Tuesday, May 21 at 1pm ET in New York City
The Jefferies 2013 Global Healthcare Conference on Tuesday, June 4 at 1:30pm ET in New York City, and
The Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11 at 1:20pm PT in Rancho Palos Verdes
The presentations w... |
|  | | 04/29/13 | Luminex Corporation Reports First Quarter 2013 Results| GAINED FDA CLEARANCE FOR NOVEL GASTROINTESTINAL PATHOGEN PANEL
AUSTIN, Texas, April 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2013. Financial and operating highlights include the following:
Consolidated first quarter revenue was $53.2 million, a 9 percent increase over the first quarter of 2012
Consolidated gross profit margin was 71 percent for the first quarter of 2013, compared to 69 percent... |
| | | 04/15/13 | Luminex Corporation Receives U.S. FDA Clearance for MAGPIX® Instrument with Novel xTAG® Gastrointestinal Pathogen Panel| Innovative multiplexing instrument for clinical laboratories with simultaneous testing for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test now available
AUSTIN, Texas, April 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). This is the first clinical assay to be c... |
| | | 04/08/13 | Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013| AUSTIN, Texas, April 8, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the first quarter of 2013 on Monday, April 29, 2013 after the close of trading.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2013 on April 29, 2013, at 5:00 p.m. Eastern time.
The conference call will b... |
| | | 03/13/13 | Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease| Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck’s Lead Investigational Medicine for Alzheimer’s Disease
WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Mar. 13, 2013-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck'... |
| | | 02/04/13 | Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results|
AUSTIN, Texas, Feb. 4, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2012. Financial and operating highlights include the following:
Consolidated fourth quarter revenue of $55.5 million, a 16 percent increase over the fourth quarter of 2011; full-year 2012 revenue was $202.6 million, a 10 percent increase over 2011
Fourth quarter assay revenue of $23.8 million, a 45 percent increase over th... |
| | | 01/31/13 | Luminex Corporation To Present At Leerink Swann Global Healthcare Conference|
AUSTIN, Texas, Jan. 31, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Leerink Swann Global Healthcare Conference to be held February 13 -14, 2013, in New York, NY.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 11:30 a.m. Eastern time on Thursday, February 14, 2013. The presentation will be webcast live an... |
| | | 01/16/13 | Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 4, 2013|
AUSTIN, Texas, Jan. 16, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter of 2012 on Monday, February 4, 2013. A press release announcing the results is scheduled for release after the close of trading.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended ... |
| | | 01/15/13 | Luminex Receives FDA Clearance for First Comprehensive Gastrointestinal Pathogen Infectious Disease Diagnostic in the United States| xTAG® Gastrointestinal Pathogen Panel (GPP) simultaneously tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test.
AUSTIN, Texas, Jan. 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), the first comprehensive molecular diagnostic assay that tests for greater than 90% of bacterial, viral, and para... |
| | | 01/02/13 | Luminex Corporation To Present At JP Morgan Healthcare Conference|
AUSTIN, Texas, Jan. 2, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 31st Annual JP Morgan Healthcare Conference to be held January 7 -10, 2013, in San Francisco, CA.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, January 9, 2013. The presentatio... |
| |
|
